ENDOMETRIOID ADENOCARCINOMA
Clinical trials for ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy double punch may beat single drug for returning uterine cancer
Disease control Recruiting nowThis study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants wi…
Matched conditions: ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Major study tracks cancer return and swelling risk in endometrial patients
Knowledge-focused Recruiting nowThis study follows 1715 people with early-stage endometrial cancer to see how often the cancer comes back after standard treatment and how often lymphedema (swelling) occurs. Participants are checked every 6 months for 3 years. The goal is to better understand outcomes and improv…
Matched conditions: ENDOMETRIOID ADENOCARCINOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC